Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Targeting of rifamycin SV to the colon for treatment of travelers' diarrhea: a randomized, double-blind, placebo-controlled phase 3 study.

DuPont HL, Petersen A, Zhao J, Mundt A, Jiang ZD, Miller S, Flores J, Shringarpure R, Moro L, Bagin RG, Ballard ED, Totoritis MC.

J Travel Med. 2014 Nov-Dec;21(6):369-76. doi: 10.1111/jtm.12168.

2.

Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial.

Riedl MA, Bernstein JA, Li H, Reshef A, Lumry W, Moldovan D, Farkas H, Levy R, Baker J, Hardiman Y, Totoritis MC, Relan A, Cicardi M; Study 1310 Investigators.

Ann Allergy Asthma Immunol. 2014 Feb;112(2):163-169.e1. doi: 10.1016/j.anai.2013.12.004. Epub 2014 Jan 7.

PMID:
24468257
3.

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC; REFLEX Trial Group.

Arthritis Rheum. 2006 Sep;54(9):2793-806.

4.

Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis.

Gottlieb AB, Kang S, Linden KG, Lebwohl M, Menter A, Abdulghani AA, Goldfarb M, Chieffo N, Totoritis MC.

Clin Immunol. 2004 Apr;111(1):28-37.

PMID:
15093549
5.

B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.

Shaw T, Quan J, Totoritis MC.

Ann Rheum Dis. 2003 Nov;62 Suppl 2:ii55-9. Review. No abstract available.

6.

Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial.

Rosenwasser LJ, Busse WW, Lizambri RG, Olejnik TA, Totoritis MC.

J Allergy Clin Immunol. 2003 Sep;112(3):563-70.

PMID:
13679816
7.

Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis.

Hepburn TW, Totoritis MC, Davis CB.

Rheumatology (Oxford). 2003 Jan;42(1):54-61.

PMID:
12509613
8.

Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.

Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D; IDEC-131 Lupus Study Group.

Arthritis Rheum. 2002 Dec;46(12):3251-8.

9.

Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody.

Gottlieb AB, Lebwohl M, Totoritis MC, Abdulghani AA, Shuey SR, Romano P, Chaudhari U, Allen RS, Lizambri RG.

J Am Acad Dermatol. 2002 Nov;47(5):692-700.

PMID:
12399760
10.

CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis.

Mason U, Aldrich J, Breedveld F, Davis CB, Elliott M, Jackson M, Jorgensen C, Keystone E, Levy R, Tesser J, Totoritis M, Truneh A, Weisman M, Wiesenhutter C, Yocum D, Zhu J.

J Rheumatol. 2002 Feb;29(2):220-9.

PMID:
11838838
11.

Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus.

Davis JC Jr, Totoritis MC, Rosenberg J, Sklenar TA, Wofsy D.

J Rheumatol. 2001 Jan;28(1):95-101.

PMID:
11196549
12.

A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis.

Mould DR, Davis CB, Minthorn EA, Kwok DC, Elliott MJ, Luggen ME, Totoritis MC.

Clin Pharmacol Ther. 1999 Sep;66(3):246-57.

PMID:
10511060
13.

A multicenter clinical trial of a biosynthetic skin replacement, Dermagraft-TC, compared with cryopreserved human cadaver skin for temporary coverage of excised burn wounds.

Purdue GF, Hunt JL, Still JM Jr, Law EJ, Herndon DN, Goldfarb IW, Schiller WR, Hansbrough JF, Hickerson WL, Himel HN, Kealey GP, Twomey J, Missavage AE, Solem LD, Davis M, Totoritis M, Gentzkow GD.

J Burn Care Rehabil. 1997 Jan-Feb;18(1 Pt 1):52-7.

PMID:
9063788
14.

IgG but not other classes of anti-[(H2A-H2B)-DNA] is an early sign of procainamide-induced lupus.

Rubin RL, Burlingame RW, Arnott JE, Totoritis MC, McNally EM, Johnson AD.

J Immunol. 1995 Mar 1;154(5):2483-93.

PMID:
7868914
15.

Association of antibody to histone complex H2A-H2B with symptomatic procainamide-induced lupus.

Totoritis MC, Tan EM, McNally EM, Rubin RL.

N Engl J Med. 1988 Jun 2;318(22):1431-6. Erratum in: N Engl J Med 1988 Jul 28;319(4):256.

PMID:
3259287
16.

Drug-induced lupus. Genetic, clinical, and laboratory features.

Totoritis MC, Rubin RL.

Postgrad Med. 1985 Sep 1;78(3):149-52, 155-61.

PMID:
3875843

Supplemental Content

Loading ...
Support Center